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Summary. Glutamic acid represents the most abundant 
stimulatory neurotransmitter in the central nervous 
system. Monosodium glutamate (MSC), subcutaneously 
administered to newborn rats in the perinatal period, 
induces lesions in 80 to 90% of the neurocytes of arcuate 
nuclei in the hypothalamus. These nuclei are the site of 
production of numerous stimulatory and inhibitory 
hormones including growth hormone releasing hormone 
(GHRH). 
The present studies were performed on male Wistar 
strain rats, subcutaneously injected on days 2, 4, 6, 8, 
and 10 of postnatal life with MSC at a dose of 4 mglg 
body weight. Eighteen-month-old rats were additionally 
treated with Ambinon. When the animals reached the 
ages of 6 or 12 months, their body weight, body length 
and weight of pituitary were determined. On parafrin 
sections, using imrnunohistochemical techniques, TSH- 
immunoreactive cells were detected and characterised by 
computerised image analysis. The results were subjected 
to statistical analysis using Student's t test. 
The rats which were perinatally treated with MSC 
and examined after 6 or 12 months of life were obese 
and shorter than control rats by 7% and 10% 
respectively. They also exhibited a reduction in the 
weight of the pituitary of 30% and 40% respectively in 
the two age groups. 
The proportion of TSH-immunoreactive cells in the 
pituitary remained unchanged and amounted to 4.5% in 
the 6-month-old and 5.4% in the 12-month-old rats 
respectively. The number of TSH-positive cells per mm 2 
area remained unchanged. The area and circumference 
of the cells in the 12-month-old rats were reduced by 
22% and 18%, respectively. 
Perinatal injury to hypophyseal arcuate nuclei 
induced by monosodium glutamate injection, was not 
associated with any significant alterations in pituitary 
structure, as defined by the proportion of pituitary 
volume occupied by TSH-immunoreactive cells. 
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Introduction 
Glutamic acid i s  one of the most abundant 
stimulatory neurotransmitters in the central nervous 
system and is also one of the amino acids most widely 
present in food.  Monosodium glutamate (MSG), 
introduced to rodents at a time when the blood brain 
barrier (BBB) has not yet sufficiently developed, i.e. in 
the perinatal period, easily penetrates the brain, 
damaging as many as 80% to 90% of the neurocytes of 
hypothalamic arcuate nuclei (Olney, 1969; Waxman, 
1990). MSC administration in neonatal rats caused 
reversible changes in BBB permeability.  BBB 
vulnerability in MSC-treated rats during immobilization 
stress exposure was increased in the hypothalamus and 
decreased in the brain stem (Skultetyova et al., 1998). 
MSC did not alter neurohypophyseal vasopressin (VP) 
profiles: VP content of the posterior pituitary and 
microdissected regions of the hypothalarnus, serum VP 
concentration were similar in MSC-treated and control 
rats (Clough et al., 1986). However, Johnston and 
Negro-Vilar (1986) examined the effect of neonatal 
MSC treatment on oxytocin,  vasopressin and 
somatostatin concentration in the suprachiasmatic, 
paraventricular, supraoptic and arcuate nuclei, median 
eminence and neurointermediate pituitary lobe. The data 
demonstrate that changes in neuropeptide content are not 
limited to the arcuate nucleus. However, MSC neonatal 
treatment resulted in a substantial loss of the arcuate 
nucleus (AN) neurons. The AN neurons produce a 
number of neuropeptides, including somatoliberin, 
somatostatin, gonadoliberin, substance P, substance K, 
NPY and 13-endorphins (Dawson and Bierkamper, 1987; 
Magarinos et al., 1988; Mitsushi et al., 1990; Jessop et 
al., 1991; Sasaki et al., 1994). 
Perinatal injection of MSC results in a number of 
endocrine-behavioural alterations. These alterations may 
be classified as either stimulatory, e.g. those related to 
lipid metabolism, or inhibitory, e.g. those affecting the 
pituitary-gonadal axis (MiSkowiak et al., 1993a,b; 




